Atlas
Back to RCM
Founder / Operator·RCM

Akash Magoon

Co-Founder and Chief Executive Officer at Adonis

New York, NY

AM
LinkedIn
Why they matter

Repeat healthcare-tech founder running one of the fastest-growing AI RCM platforms, with $95M+ raised, 4x 2025 revenue growth, and firsthand visibility into provider revenue-cycle pain.

Background

Akash Magoon is Co-Founder and CEO of Adonis, a New York-based AI orchestration platform for healthcare revenue cycle management he founded in 2022 with his brother Aman. Previously he co-founded insurtech Nayya in 2019, serving as CTO, and was named to the Forbes 30 Under 30 list in 2022. He has raised over $95 million for Adonis across three rounds from investors including Quadrille Capital, Point72, and General Catalyst.

Notable deals

  • 2026
    Raised $40M Series C for Adonis led by Quadrille Capital, bringing total funding past $95M after 4x revenue growth in 2025
  • 2024
    Raised $31M Series B for Adonis led by Point72 Private Investments to expand AI-driven revenue recovery for providers
  • 2023
    Raised $17.3M Series A for Adonis led by General Catalyst, one year after founding the company
  • 2022
    Named to Forbes 30 Under 30 as co-founder and CTO of insurtech Nayya

Call-prep brief

Background

  • Co-Founder & CEO of Adonis (founded 2022, NYC) with his brother Aman Magoon; previously co-founded insurtech Nayya (2019) as CTO. Forbes 30 Under 30 (2022), University of Maryland '18, earlier stints at AWS and Enigma.
  • Has raised $95M+ for Adonis: $17.3M Series A (General Catalyst, 2023), $31M Series B (Point72, 2024), $40M Series C (Quadrille Capital, March 2026).

Current focus

  • Scaling Adonis's AI orchestration platform across the full revenue cycle — eligibility, claims, denials, appeals — and moving upmarket from practices into health systems.
  • Reported 4x revenue growth in 2025 with net retention above 130%.

What they care about

  • Structural RCM problems: workforce shortages, rising denial rates, underpayments. Positions Adonis as automation that recovers revenue providers are owed, framed around customer outcomes and patient experience.

Recent moves

  • Closed the $40M Series C in March 2026; expanding the New York team and pushing deeper into AI-driven denials management.

Potential sensitivities

  • Well-capitalized and growing fast, so unlikely to engage on acquisition framing; competitive RCM-AI landscape means he may guard pipeline and product-roadmap detail. Nayya history is public but he has fully moved on.

Questions to ask

  • Which RCM subsegments (denials, eligibility, underpayments) show the strongest willingness to pay, and where is ROI hardest to prove?
  • How do health-system sales cycles and integration burdens differ from the practice segment Adonis started in?
  • Where does he see consolidation coming in RCM — legacy outsourcers acquiring AI, or AI-native platforms displacing them?

Outreach draft

Subject
AI in revenue cycle — your perspective
Hi Akash, Congratulations on the Series C — the growth Adonis has posted since 2022 stands out even in a crowded RCM field. I'm on the investment team at a private equity firm evaluating opportunities across healthcare revenue-cycle software and services, and we're forming a view on where AI-native platforms will displace legacy RCM vendors versus augment them. Your vantage point as a repeat founder who has built in both benefits and revenue cycle would be genuinely valuable. Would you be open to a 30-minute call in the next couple of weeks? Happy to share our thesis and where we see the market heading. Best, [NAME]

Linked companies

Sources